India finally includes heart stents among essential medical items, draws industry flak

India flag

India has finally decided to place caps on the prices of at least two categories of heart stents with the issue going back and forth for the past year. The move drew brickbats from a manufacturing industry lobby group.

The two categories--drug-eluting and bare metal--heart stents will be included in the country's National List of Essential Medicines, according to the Economic Times, setting the stage for the National Pharmaceutical Pricing Authority to set price caps that could see a drop of 40% to 70% from current levels, according to earlier reports.

The decision to include stents in the essential category of medicines and devices comes as coronary disease in India rises as a public health hazard, with the cost of the devices playing a key factor in seeking surgery for patients paying out-of-pocket.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

A sub-committee of expert cardiologists had recommended the caps and the details on pricing are expected soon.

In a press release, the Confederation of Indian Industry said the move was counterproductive to efforts to encourage medical device manufacturing in the country--a key aim of the government led by Prime Minister Narendra Modi.

"(The move) is detrimental to the nascent medical device industry committed to improve access to quality healthcare and medical devices in India," the industry body said in a statement.

As well, a lobby group for multinational device makers such as Abbott Laboratories ($ABT) and Medtronic ($MDT), the Advanced Medical Technology Association, criticized the decision as not taking quality variations into account.

At stake is a market that has trebled over the last 5 years in India, the newspaper said, citing the National Interventional Council, with 500,000 stents implanted in 2015.

Current prices for drug-eluting stents in India ranged between INR23,625 ($351.77) to INR150,000 ($2,233.50), the newspaper said, adding they account for 95% of the stents used in surgery cases.

- here's the story from the Economic Times

Related Articles:
India moving closer to implementing price controls on medical devices

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.